reintroduce the bill, the
opposition party too
must support. And if
I remember correctly,
Mr Shashi Tharoor had
supported it earlier but
with few amendments. We
as an industry association
have pressed to DBT
for making it a reality. I
sincerely wish it comes
through.
How do you look at
the regulatory issues
especially in case of
clinical trials? Hope
can we change the
situation?
The global companies had
put lot of investments
into their CRO work,
drug discovery, early
stage discovery etc. We
completely drove them
away with our facts and
figures on clinical trial
deaths. We knee jerked
badly to any episode.
Either we didn’t put
enough checks and
balances or we simply lost
the plot.
Today this industry is
global. If they didn’t get
the environment here,
they left for other better
destinations. We cold
shoulder everybody who
wants to come here for
investments through our
acts. I am not simply
blaming government but
all of us, the stakeholders.
Time has come to pull
our efforts in sync with
each other to come out of
this situation and present
India again as a right
destination.
Many people tell me
that while BIRAC has
been doing a good
job, we require more
BIRACs. Do you
agree?
All the new
emerging
areas can
contribute
tremendously in
overall growth of
the biotech sector.
It is ultimately
what the PM Modi
said: ‘The more you
do the business,
economy develops
and so does the
sector on its own’
It is self-fueling.
BIOVOICENEWS.COM
13